Venrock Healthcare Capital Partners III L.P. 13D and 13G filings for Enliven Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 5:48 pm Purchase |
2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN |
Venrock Healthcare Capital Partners III L.P. | 4,026,331 8.500% |
1,071,429 (+36.26%) |
Filing |
| 2024-02-14 8:53 pm Purchase |
2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
Venrock Healthcare Capital Partners III L.P. | 2,954,902 7.200% |
740,760 (+33.46%) |
Filing |
| 2023-03-13 4:01 pm Purchase |
2023-03-03 | 13G | Enliven Therapeutics, Inc. ELVN |
Venrock Healthcare Capital Partners III L.P. | 2,214,142 5.400% |
2,214,142 (New Position) |
Filing |